NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
Clinical Trials
253 trialsNCT03693807 2026-02-06
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00556413 2026-02-05
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT00873275 2025-06-22
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03206151 2025-05-23
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT04761614 2025-03-28
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00059930 2025-03-26
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04072198 2025-03-13
NIVACOR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT05178745 2025-01-30
Resection Observatory
Sanofi
Completed
NCT04513951 2025-01-09
AVETRIC
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02705300 2024-08-29
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
Vejle Hospital
Phase 2 Completed
NCT00321828 2024-03-21
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NSABP Foundation Inc
Phase 2 Completed
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT03414983 2023-11-18
CheckMate 9X8
Bristol-Myers Squibb
Phase 2/3 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT03721653 2023-10-12
AtezoTRIBE
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT00343408 2023-08-04
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT00098787 2023-07-05
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT01328171 2023-06-15
VOLFI
AIO-Studien-gGmbH
Phase 2 Completed
NCT01991873 2023-06-15
PanaMa
AIO-Studien-gGmbH
Phase 2 Completed
NCT01420874 2023-05-06
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT03279289 2023-04-13
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT00202774 2023-04-12
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT03231722 2023-01-05
TRIPLETE
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT00642577 2022-12-22
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00467142 2022-11-01
OMEGA
Institut Bergonié
Phase 2 Completed
NCT00199797 2022-10-10
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT00280761 2022-08-11
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
UNC Lineberger Comprehensive Cancer Center
Completed
NCT01516216 2022-04-26
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02641873 2022-04-12
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT04425239 2022-04-07
IMPROVE
National Cancer Institute, Naples
Phase 2 Completed
NCT04247984 2022-03-11
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Completed
NCT00308516 2021-12-10
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed